TICKERNERD
Menu
PCRXPCRXHealthcare · Drug Manufacturers - Specialty & Generic

PCRX Stock Forecast: Pacira Biosciences, Inc. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$36
+0.05% on the day

The 9 Wall Street analysts covering Pacira Biosciences, Inc. hold a median 12-month price target of $37 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
100/ 100
Median analyst target
$37
Analysts covering
9
Revenue$192.4M+6.2% y/y
Operating income$11.9M
Net income$4.7M
Free cash flow$56.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
+44.9%
YTD
+40.6%
1Y
+70.7%
From 52W high
−0.1%
From 52W low
+90.0%
$19
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pacira Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
100/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
100
Accruals
99
Value
98
Quality
94
Volatility
92
Momentum
79
Growth
78
Revisions
66
Size
39

Issuance (100): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (66): Analysts have, on balance, been cutting their forecasts.

Size (39): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Jan 26Apr 26Jul 26Oct 26PCRXHigh $37Median $37Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
0 Buy9 Hold0 Sell
Low $25Median $37High $37

The green dot is the last close — the median target sits +0.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
9 Oct 2026HC Wainwright & Co.DowngradeNeutral$38 → $37
9 Oct 2026RBC CapitalMaintainsSector Perform$25 → $37
9 Oct 2026Truist SecuritiesDowngradeHold$31 → $37
8 Oct 2026JefferiesDowngradeHold$36
8 Oct 2026JP MorganUpgradeNeutral$37
8 Oct 2026NeedhamDowngradeHold—
7 Oct 2026Truist SecuritiesMaintainsBuy$30 → $31
23 Sept 2026OppenheimerInitiatesOutperform—
23 Sept 2026OppenheimerInitiatesOutperform$32
9 Sept 2026Leerink PartnersInitiatesMarket Perform—
9 Sept 2026Leerink PartnersInitiatesMarket Perform$28
5 Aug 2026NeedhamMaintainsBuy$32 → $33
5 Aug 2026NeedhamMaintainsBuy—
5 Aug 2026RBC CapitalMaintainsSector Perform$24 → $25
5 Aug 2026RBC CapitalMaintainsSector Perform—
1 July 2026HC Wainwright & Co.ReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$38
1 May 2026NeedhamMaintainsBuy—
1 May 2026RBC CapitalMaintainsSector Perform—
26 Mar 2026BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PCRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

PCRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Pacira Biosciences, Inc. returned +70.7% against +13.5% for the S&P 500, dividends included.

PCRX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26PCRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
1
Analysts cutting
0
Fundamentals

Pacira Biosciences, Inc. (PCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
104.1×

Cheaper than 7% of US stocks

Price / sales
1.9×

Cheaper than 52% of US stocks

Price / book
2.2×

Cheaper than 40% of US stocks

EV / EBITDA
13.0×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
6.2%

Higher than 43% of US stocks

Earnings growth (YoY)
6.2%

Higher than 43% of US stocks

Gross margin
77.0%

Higher than 89% of US stocks

Operating margin
6.2%

Higher than 57% of US stocks

Net margin
2.0%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.5%

Higher than 55% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pacira Biosciences, Inc. (PCRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pacira Biosciences, Inc. has a market value of $1.5B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $746.2M. The latest quarter grew 6.2% year on year.

  • Net income over the same four quarters: $14.6M, a 2.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.35.

  • Free cash flow in the twelve months to 30 June 2026: $179.5M.

  • Pacira Biosciences, Inc. spent $148.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 39.8M.

  • Trailing P/E: 104.1×; forward P/E: 10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pacira Biosciences, Inc. employs 825 people — $904K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

PCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PCRXPacira Biosciences, Inc.$1.5B100
ETONEton Pharmaceuticals, Inc.$1.5B99
PAHCPhibro Animal Health Corp.$1.6B90
ANIPANI Pharmaceuticals, Inc.$1.6B95
ALVOAlvotech$1.9B32
XERSXeris Biopharma Holdings, Inc.$1.9B85
AMPHAmphastar Pharmaceuticals, Inc.$1.1B88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pacira Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCRX news & analysis

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

Business Wire · 12 Oct 2026neutral

Kahn Swick & Foti, LLC said it is investigating the proposed sale of Pacira BioSciences to Viatris, including the adequacy of the $36.50-per-share cash consideration and the process leading to the transaction.

Why it matters — The investigation concerns the proposed transaction’s terms and process, matters relevant to Pacira shareholders following the announcement.

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Zacks Investment Research · 9 Oct 2026positive

Viatris is set to acquire Pacira Biosciences for $1.65 billion in cash. The deal would add two marketed pain therapies and a clinical-stage gene therapy candidate to Viatris’ non-opioid pain portfolio.

Why it matters — The acquisition would expand the portfolio and ownership context for Pacira’s marketed pain therapies and gene therapy candidate.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

Newsfile Corp · 8 Oct 2026negative

Brodsky & Smith said it is investigating potential claims against Pacira BioSciences’ board related to the company’s proposed sale to Viatris for $36.50 per share in cash, or an aggregate equity value of $1.65 billion. The investigation concerns whether the board fulfilled its fiduciary duties, including whether the transaction process was fair and the proposed price represents fair value for shareholders.

Why it matters — The investigation raises questions about the sale process and the value shareholders may receive in the proposed transaction.

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

PRNewsWire · 8 Oct 2026neutral

Ademi LLP is investigating whether Viatris's proposed acquisition of Pacira fairly values public shareholders and whether Pacira's board protected their interests. The excerpt says shareholders would receive $36.50 per share in cash, and the firm is also examining insider benefits and restrictions on competing offers.

Why it matters — The investigation concerns the proposed deal's per-share consideration and the board's handling of the transaction, issues relevant to PCRX shareholders.

2 Stocks Drawing Bearish Options Activity Today

Schaeffers Research · 8 Oct 2026negative

Schaeffers Research reports that options traders are taking a bearish stance on Pacira BioSciences (PCRX), which is among two stocks attracting unusual options volume today.

Why it matters — The report highlights bearish options activity in PCRX, a trading signal of interest to investors following the stock.

FAQ

Frequently asked questions about PCRX stock

What is the PCRX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Pacira Biosciences, Inc. have a median 12-month price target of $37, with estimates ranging from $25 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCRX stock a buy right now?

Of the 9 analysts covering Pacira Biosciences, Inc., 0 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pacira Biosciences, Inc. 100 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCRX?

As at 27 Oct 2026, Pacira Biosciences, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (100 of 100).

Will PCRX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Pacira Biosciences, Inc. 100 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCRX stock forecast for 2030?

No analyst covering Pacira Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $37 over the next 12 months.

How has PCRX stock performed over the past year?

Pacira Biosciences, Inc. returned +70.7% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pacira Biosciences, Inc. do?

Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions.

What is the latest news on PCRX?

The most recent item we track (Business Wire, 12 Oct 2026): "Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX". Kahn Swick & Foti, LLC said it is investigating the proposed sale of Pacira BioSciences to Viatris, including the adequacy of the $36.50-per-share cash consideration and the process leading to the transaction.

Company

About Pacira Biosciences, Inc.

Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions. Pacira BioSciences develops, manufactures, markets, distributes, and sells therapies used across postsurgical, chronic, and musculoskeletal pain settings, serving healthcare practitioners in the United States. Its commercial portfolio includes EXPAREL, a long-acting local anesthetic used in surgical pain control, ZILRETTA, an extended-release injectable treatment for knee osteoarthritis pain, and iovera°, a handheld device that delivers targeted cold therapy for drug-free pain relief. The company also advances pipeline programs such as PCRX-201, a locally administered gene therapy candidate being studied for osteoarthritis of the knee. Pacira BioSciences plays a notable role in the pain-treatment market by offering alternatives designed to reduce reliance on opioids while supporting patient recovery and function.

CEO Mr. Frank D. Lee · 825 employees · United States · https://www.pacira.com